

Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of *TLX3/HOX11L2* gene expression on outcome

Paola Ballerini,¹ Judith Landman-Parker,^{2*} Jean Michel Cayuela,³ Vahid Asnafi,⁴ Myriam Labopin,^{5*} Virginie Gandemer,⁶ Yves Perel,⁷ Gérard Michel,⁸ Thierry Leblanc,⁹ Claudine Schmitt,¹⁰ Sylvie Fasola,² Anne Hagemejier,¹¹ François Sigaux,³ Marie Françoise Auclerc,⁹ Luc Douay,^{1*} Guy Leverger,^{2*} and André Baruchel⁹

¹Laboratory of Hematology, Hôpital d'Enfants Armand Trousseau APHP; ²Department of Pediatric Hematology Oncology and ^{*}Unité INSERM 832, Université Pierre et Marie Curie-Paris 6, Paris; ³Laboratory of Hematology, Hôpital Saint Louis, APHP, Paris; ⁴Laboratory of Hematology, Hôpital Necker Enfants Malades APHP, Paris; ⁵CEREST-TC, Hôpital Saint Antoine, Université Pierre et Marie Curie-Paris 6; ⁶Department of Pediatrics, Onco-hematology Unit, CHRU, Hôpital Sud, Rennes; ⁷Department of Pediatric Hematology and Oncology, Groupe Hospitalier Pellerin, Bordeaux; ⁸Department of Hematology, Hôpital La Timone, Marseille; ⁹Department of Hematology, Hôpital Saint Louis, APHP, Paris; ¹⁰Department of Oncology and Hematology, Hôpital d'Enfants Vandoeuvres, Les Nancy, France; ¹¹Department of Human Genetics, University of Leuven, Leuven, Belgium

Citation: Ballerini P, Landman-Parker J, Cayuela J, Asnafi V, Labopin M, Gandemer V, Perel Y, Michel G, Leblanc T, Schmitt C, Fasola S, Hagemejier A, Sigaux F, Auclerc MF, Douay L, Leverger G and Baruchel A. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of *TLX3/HOX11L2* gene expression predicts on outcome. *Haematologica* 2008; doi.10.3324/haematol.13291

INDUCTION	VCR 1,5mg/m ² /d IV D8, D15, D22, D29 PRED 60mg/m ² /d D1 -D7, 40mg/m ² /d D8-D21 L-Aspa 10000UI/m ² /d IM x 8 D20-D35 DNR 40mg/m ² /d D8 -D9-D10 -D15 D22
CONSOLIDATION	VP16 150mg/m ² /d IV D1, D8, D15 Cyt 30mg/m ² x 2/d D1, D2, D8, D9, D15, D16 Thioguanine 60mg/m ² /d PO D1 -D21 PRED 40mg/m ² /d PO D29 -D36 VCR 1,5mg/m ² /d IV D29, D57 6-MP 50mg/m ² /d PO D29 -D50 LD MTX 25mg/m ² /d PO D29, D36, D43 or HD MTX 8000mg/m ² /d D29, D43 (children < 4 years)
INTENSIFICATION n°1.1 (D1 -D28) :	INTENSIFICATION N° 1.2 (D28-D49):
DEX 10mg/m ² /d PO/IV D1-D14, depressive D15-D22	Cyt 30mg/m ² x 2/d D29, D30, D36, D37, D43, D44
VDS 3mg/m ² /d IV D1, D8, D15	Thioguanine 60mg/m ² /d PO D29-D49
ADRIA 25mg/m ² /d IV D1, D8, D15	
L-Aspa 6000UI/m ² /d IV/IM D1, D3, D5, D8, D10, D12	
VP16 150mg/m ² /d IV D29, D36, D43	
INTERPHASE : PRED 40mg/m ² /d PO D1 -D8, D29 -D36	
VCR 1,5mg/m ² /d IV D1, D29 -MP 50mg/m ² /d PO D1-D49	
LD MTX 25mg/m ² /d PO D1, D8, D15, D22, D29, D36	
or HD MTX 8000mg/m ² /d D1, D15 (children < 4 years)	
INTENSIFICATION n°2.1 (D1 -D28)	INTENSIFICATION n°2.1 (D29 -D57))
PRED 40mg/m ² /d PO D1 -D14,	VP16 150mg/m ² /d IV D29-D43
VDS 3mg/m ² /d IV D1, D8, D15	Cyt 30mg/m ² x 2/d D29, D30, D43, D44
L-Aspa 6000UI/m ² /d IV/IM D1, D3, D5, D8, D10, D12	Thioguanine 60mg/m ² /d PO D29-D49
DNR 30mg/m ² /d D1 -D8-D15	
MAINTENANCE (18 months) : 6 pulse (4 weeks) VCR 1,5mg/m ² /d IV D1 /PRED 40mg/m ² /d PO D1-D7	
6 6-MP 75mg/m ² /d x weeks / MTX 25mg/m ² /d PO x weeks	